E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/25/2005 in the Prospect News Biotech Daily.

Jefferies maintains Parexel at market underperform

Parexel International Corp. was maintained by Jefferies & Co. Inc. analyst David Windley at a market underperform rating and the price target was raised to $19.00 from $17.25 on news that the company's new business in the first quarter was impressive. But, even after restructuring cuts, resources still are out of balance in the loss-making U.S. segment. Shares of the Waltham, Mass.-based biopharmaceutical company were down $0.18, or 0.84%, at $21.15 on volume of 119,717 shares versus the three-month running average of 121,966 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.